How the CBTC Operates

Based at Toronto's Sunnybrook Health Sciences Centre, CBTC Headquarters regularly receives queries, often channeled by its Members, from industry and other interested parties. CBTC Headquarters is equipped to quickly provide centralized communications for a variety of projects such as feasibility surveys, expedited reviews of clinical trials, capabilities of research sites or membership on advisory boards for example.

Potential study sponsors deal directly with the consortium instead of contacting each individual site. The full membership is continuously informed of the projects proposed to the Consortium and what stage of development they may be in.

CBTC Funding:

Industry Projects:

• Grants in AID: paid directly to investigators
• CBTC Corporate Agreements: paid directly to CBTC Corporation Expedited Review Charges - pass through costs reimbursed by Sponsor Consultancy Fees (Steering Committees / Advisory Boards) - paid to CBTC Corporation - 100% redirected to CBTC Members who have met obligations.

CBTC Corporate Agreements:

After a project or clinical trial has successfully undergone CBTC Expedited Review, a corporate agreement is reached between CBTC and the sponsor to move forward with the project or clinical trial. CBTC then negotiates a performance based corporate agreement with the sponsor and/or requests a grant-in-aid.

There are 2 basic components to this agreement:

a.     Project Management Fee:

A flat rate project management fee to cover the administrative costs incurred throughout the duration of the project or study.

b.     Performance Based Accrual (PBA) Charge:

In addition to the project management fee, the Sponsor is required to pay CBTC a specified amount for every patient entering the project or clinical trial across all CBTC participating sites. The full cash value of the agreement is calculated by multiplying the number of subjects enrolled in a given study by a percentage of the per-case funding. An estimate of the PBA charge is pre-determined between the Sponsor and the Consortium, and adjusted accordingly over the progression of the study.

The CBTC directs revenues generated from Sponsor Agreements to fund the collective academic, research, corporate and administrative objectives of the Consortium. In return the CBTC offers the following value-added services which are of shared benefit to the medical community, pharmaceutical industry both locally and abroad.